I 117TH CONGRESS 1ST SESSION H. R. 1686 To direct the Comptroller General of the United States to evaluate and report on the inpatient and outpatient treatment capacity, availability, and needs of the United States. IN THE HOUSE OF REPRESENTATIVES MARCH 9, 2021 Mr. FOSTER introduced the following bill; which was referred to the Com- mittee on Energy and Commerce, and in addition to the Committee on Natural Resources, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To direct the Comptroller General of the United States to evaluate and report on the inpatient and outpatient treatment capacity, availability, and needs of the United States. Be it enacted by the Senate and House of Representa- 1 tives of the United States of America in Congress assembled, 2 SECTION 1. SHORT TITLE. 3 This Act may be cited as the ‘‘Examining Opioid 4 Treatment Infrastructure Act of 2021’’. 5 VerDate Sep 11 2014 03:04 May 01, 2021 Jkt 019200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H1686.IH H1686 kjohnson on DSK79L0C42PROD with BILLS 2 •HR 1686 IH SEC. 2. STUDY ON TREATMENT INFRASTRUCTURE. 1 Not later than 24 months after the date of enactment 2 of this Act, the Comptroller General of the United States 3 shall initiate an evaluation of, and submit to Congress a 4 report on, the inpatient and outpatient treatment capacity, 5 availability, and needs of the United States, including, to 6 the extent data are available— 7 (1) the capacity of acute residential or inpatient 8 detoxification programs; 9 (2) the capacity of inpatient clinical stabiliza- 10 tion programs, transitional residential support serv- 11 ices, and residential rehabilitation programs; 12 (3) the capacity of demographic specific resi- 13 dential or inpatient treatment programs, such as 14 those designed for pregnant women or adolescents; 15 (4) geographical differences of the availability 16 of residential and outpatient treatment and recovery 17 options for substance use disorders across the con- 18 tinuum of care; 19 (5) the availability of residential and outpatient 20 treatment programs that offer treatment options 21 based on reliable scientific evidence of efficacy for 22 the treatment of substance use disorders, including 23 the use of Food and Drug Administration-approved 24 medicines and evidence-based nonpharmacological 25 therapies; 26 VerDate Sep 11 2014 03:04 May 01, 2021 Jkt 019200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H1686.IH H1686 kjohnson on DSK79L0C42PROD with BILLS 3 •HR 1686 IH (6) the number of patients in residential and 1 specialty outpatient treatment services for substance 2 use disorders; 3 (7) an assessment of the need for residential 4 and outpatient treatment for substance use disorders 5 across the continuum of care; 6 (8) the availability of residential and outpatient 7 treatment programs to American Indians and Alaska 8 Natives through an Indian health program (as de- 9 fined by section 4 of the Indian Health Care Im- 10 provement Act (25 U.S.C. 1603)); and 11 (9) the barriers (including technological bar- 12 riers) at the Federal, State, and local levels to real- 13 time reporting of de-identified information on drug 14 overdoses and ways to overcome such barriers. 15 Æ VerDate Sep 11 2014 03:04 May 01, 2021 Jkt 019200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6301 E:\BILLS\H1686.IH H1686 kjohnson on DSK79L0C42PROD with BILLS